公开(公告)号：US20180055826A1

公开(公告)日：2018-03-01

申请号：US15556055

申请日：2016-03-02

Applicant: STC. UNM

Inventor： Eric R. Prossnitz ,  Geetanjali Sharma ,  Matthias Barton ,  Matthias R. Meyer

IPC: A61K31/436 ,  A61K31/16 ,  A61K31/4355

CPC classification number: A61K31/436 ,  A61K31/16 ,  A61K31/435 ,  A61K31/4355 ,  A61K31/437 ,  A61K31/7088 ,  A61K38/28 ,  G01N2800/042

Abstract: The current invention is in the field of molecular biology/pharmacology and provides methods of using compounds that modulate the effects of GPR30/GPER for treating obesity and diabetes (preferably agonists) as well as disease states and/or conditions that result from excessive formation of reactive oxygen species (preferably antagonists). These compounds may function as agonists and/or antagonists of the disclosed estrogen receptor and/or modulate the expression/upregulation of nox and nox-associated reactive oxygen species (ROS).

公开(公告)号：US20180050097A1

公开(公告)日：2018-02-22

申请号：US15561130

申请日：2016-03-25

Applicant: STC. UNM

Inventor： Kiran Bhaskar ,  Nicole Maphis ,  David S. Peabody ,  Bryce Chackerian ,  Julianne Peabody ,  Erin Crossey

IPC: A61K39/00 ,  A01K67/027 ,  C12N7/00

CPC classification number: A61K39/0007 ,  A01K67/0278 ,  A01K2217/056 ,  A01K2217/072 ,  A01K2217/075 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/0306 ,  A01K2267/0312 ,  A01K2267/0318 ,  A01K2267/0368 ,  A61K2039/5258 ,  A61K2039/575 ,  C12N7/00 ,  C12N2795/18123 ,  C12N2795/18134 ,  C12N2795/18171

Abstract: This disclosure describes, in one aspect, immunogens effective for treating and/or diagnosing tauopathy, and immunotherapeutic compositions and methods involving those immunogens. Generally, the immunogen includes an antigen presentation component and a microtubule-associated tau protein (MAPT) component linked to at least a portion of the antigen presentation component. This disclosure describes, in another aspect, a transgenic mouse. Generally, the transgenic mouse possesses brain cells that have a polynucleotide that encodes human microtubule-associated protein tau (MAPT). The polynucleotide further exhibits a deletion of at least a portion of endogenous mouse MAPT. The transgenic mouse also includes a forebrain neuron-specific deletion of a polynucleotide that encodes Myeloid Differentiation Primary Response Gene 88 (MyD88). In a further aspect, this disclosure describes a method of producing the transgenic mouse.

公开(公告)号：US09595112B2

公开(公告)日：2017-03-14

申请号：US14722651

申请日：2015-05-27

Applicant: STC. UNM

Inventor： Paul A. Rodriquez-Valderrama ,  Brendt Wohlberg

IPC: G06T7/00

CPC classification number: G06T7/11 ,  G06K9/34 ,  G06T7/143 ,  G06T7/194 ,  G06T7/254 ,  G06T2207/10016 ,  G06T2207/20081

Abstract: An incremental Principal Component Pursuit (PCP) algorithm for video background modeling that is able to process one frame at a time while adapting to changes in background, with a computational complexity that allows for real-time processing, having a low memory footprint and is robust to translational and rotational jitter.

Abstract translation: 用于视频背景建模的增量主成分追踪（PCP）算法，能够一次处理一帧，同时适应背景变化，具有允许实时处理的计算复杂度，具有低内存占用并且稳定 到平移和旋转抖动。

公开(公告)号：US20160338954A1

公开(公告)日：2016-11-24

申请号：US15023110

申请日：2014-09-18

Applicant: STC. UNM ,  SANDIA CORPORATION

Inventor： C. Jeffrey Brinker ,  Yu-Shen Lin

IPC: A61K9/127 ,  A61K38/16 ,  C12N15/88 ,  A61K39/395 ,  A61K9/51 ,  A61K31/7088 ,  A61K38/43

CPC classification number: A61K9/1271 ,  A61K9/14 ,  A61K9/5115 ,  A61K9/5123 ,  A61K31/7088 ,  A61K38/16 ,  A61K38/43 ,  A61K39/395 ,  B82Y5/00 ,  B82Y15/00 ,  C12N15/88

Abstract: In one aspect, the invention provides novel monodisperse, colloidally-stable, torroidal mesoporous silica nanoparticles (TMSNPs) which are synthesized from ellipsoid-shaped mesoporous silica nanoparticles (MSNPs) which are prepared using an ammonia base-catalyzed method under a low surfactant conditions. Significantly, the TMSNPs can be loaded simultaneously with a small molecule active agent, a siRNA, a mRNA, a plasmid and other cargo and can be used in the diagnosis and/or treatment of a variety of disorders, including a cancer, a bacterial infection and/or a viral infection, among others. Related protocells, pharmaceutical compositions and therapeutic and diagnostic methods are also provided.

Abstract translation: 一方面，本发明提供了由在低表面活性剂条件下使用氨碱催化法制备的椭圆形介孔二氧化硅纳米粒子（MSNP）合成的新型单分散，胶体稳定的环形介孔二氧化硅纳米粒子（TMSNP）。 值得注意的是，TMSNPs可以与小分子活性剂，siRNA，mRNA，质粒和其他货物同时加载，并且可以用于诊断和/或治疗各种疾病，包括癌症，细菌感染 和/或病毒感染等。 还提供了相关的原细胞，药物组合物和治疗和诊断方法。

公开(公告)号：US20160287531A1

公开(公告)日：2016-10-06

申请号：US15036968

申请日：2014-12-05

Applicant: STC. UNM

Inventor： David L VANDER JAGT ,  Lorraine M. Deck ,  Robert E Royer ,  John E Heidrich

IPC: A61K31/12 ,  A61K31/444 ,  A61K9/00 ,  A61K31/05 ,  A61K31/136 ,  A61K45/06 ,  A61K31/222 ,  A61K31/085

CPC classification number: A61K31/12 ,  A61K9/0014 ,  A61K31/05 ,  A61K31/085 ,  A61K31/09 ,  A61K31/121 ,  A61K31/136 ,  A61K31/137 ,  A61K31/222 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/444 ,  A61K45/06

Abstract: The present invention relates to method(s) of treating a subject afflicted with a skin disease or condition, the method comprising administering to the subject or patient in need a composition comprising a therapeutically effective amount of a substituted cis or trans-stilbene or a stilbene hybrid. A method of treating or reducing the likelihood of a skin disease or condition in a patient is an additional embodiment of the present invention. Preferred pharmaceutical compositions of the invention include nanoemulsions comprising a therapeutically effective amount of a substituted cis or trans-stilbene or stilbene hybrid and at least one antibiotic.

Abstract translation: 本发明涉及治疗患有皮肤疾病或病症的受试者的方法，所述方法包括向需要的受试者或患者施用包含治疗有效量的经取代的顺式或反式二苯乙烯或二苯乙烯的组合物 混合 治疗或减少患者皮肤疾病或病症的可能性的方法是本发明的另外的实施方案。 本发明优选的药物组合物包括含有治疗有效量的取代的顺式或反式二苯乙烯或芪混合物和至少一种抗生素的纳米乳剂。

公开(公告)号：US20160151482A1

公开(公告)日：2016-06-02

申请号：US14781765

申请日：2014-04-02

Applicant: STC. UNM ,  SANDIA CORPORATION

Inventor： Eric C. Carnes ,  C. Jeffrey Brinker ,  Carlee Erin Ashley

IPC: A61K39/39 ,  A61K9/14 ,  A61K9/51

CPC classification number: A61K39/39 ,  A61K9/127 ,  A61K9/146 ,  A61K9/5115 ,  A61K9/5184 ,  A61K31/365 ,  A61K38/19 ,  A61K39/0208 ,  A61K39/07 ,  A61K39/08 ,  A61K45/06 ,  A61K47/6923 ,  A61K47/6929 ,  A61K2039/55505 ,  A61K2039/55555 ,  A61K2300/00

Abstract: The present invention relates to mesoporous alum nanoparticles which can be used as a universal platform for antigen adsorption, presentation and delivery to provide immune compositions, including vaccines and to generate an immune response (preferably, both humoral and cell mediated immune response), preferably a heightened immune response to the presentation of one or more antigens to a patient or subject.

Abstract translation: 本发明涉及介孔矾纳米颗粒，其可用作抗原吸附，呈递和递送的通用平台，以提供免疫组合物，包括疫苗和产生免疫应答（优选体液和细胞介导的免疫应答），优选为 增加对一种或多种抗原呈递给患者或受试者的免疫应答。

公开(公告)号：US20240261378A1

公开(公告)日：2024-08-08

申请号：US16321699

申请日：2017-07-31

Applicant: STC UNM

Inventor： Vojo Deretic

IPC: A61K38/53 ,  A61K31/05 ,  A61K31/137 ,  A61K31/155 ,  A61K31/436 ,  A61K31/4375 ,  A61K31/616 ,  A61K31/7016 ,  A61K31/702 ,  A61K38/17 ,  A61K45/06 ,  A61P31/04

CPC classification number: A61K38/53 ,  A61K31/05 ,  A61K31/137 ,  A61K31/155 ,  A61K31/436 ,  A61K31/4375 ,  A61K31/616 ,  A61K31/7016 ,  A61K31/702 ,  A61K38/1732 ,  A61K45/06 ,  A61P31/04

Abstract: Tie present invention relates to compositions and methods of influencing autophagy by modulating TRIM (tripartite motif containing) proteins, especially TRIM 8, TRIM: 10, TRIM 16, TRIM 19 and/or TRIM 51 (preferably TRIM 16} and galectins, especially galectins 3 m order to influence autophagy and treat a number of disease states and/or conditions which are mediated and/or influenced by autophagy, including inflammatory disease states and/or conditions, including a microbial infection such as a Mycobacterium infection, among numerous others, an inflammatory disorder, a lysosomal, storage disorder, an immune disorder, a neurodegenerative disorder and a cancer.

公开(公告)号：US20220183945A1

公开(公告)日：2022-06-16

申请号：US17438362

申请日：2020-03-10

Applicant: STC. UNM

Inventor： Dominique Renee Perez ,  Larry A. Sklar ,  Alexandre Chigaev ,  Alison F. Franks

IPC: A61K8/49 ,  A61Q19/00 ,  A61Q15/00

Abstract: The present invention is directed to previously identified inhibitors of cAMP efflux (ICE) and their use in treating/masking body odor, inhibiting, reducing and/or eliminating hyperhidrosis (excessive sweating), tanning skin or protecting skin before and/or after exposure to the sun as well as for treating certain skin conditions, in one embodiment, the invention provides a method for inhibiting body odor, a condition that is characterized by an unpleasant odor from the products of the microbial sweat degradation. By inhibiting the efflux of the precursor compounds that are degraded, novel compounds are capable of preventing unwanted odors. Deodorant compositions that employ this new approach for the control of bodily odor are provided, ICE compounds can also be used as components, of cosmetic formulations including tanning and after-sun formulations, formulations for skin conditions as described herein and other cosmetic formulation.

公开(公告)号：US20210079474A1

公开(公告)日：2021-03-18

申请号：US17050285

申请日：2019-04-25

Applicant: STC. UNM

Inventor： Nikolaos MELLIOS

IPC: C12Q1/6883

Abstract: A plurality of circular RNAs (circRNAs) the expression of which is correlated with brain disorders. The circRNAs are useful for compositions, kits, assays, and methods for the identification, diagnosis, screening, treatment and/or monitoring of brain disorders including psychiatric disorders such as bipolar disorder (BD), schizophrenia (SCZ), depression, Attention-Deficit/Hyperactivity Disorder (ADHD), Obsessive-compulsive disorder (OCD), Anxiety Disorders, etc., and neurodevelopmental disorders such as Autism, Asperger's Syndrome, and other Autism Spectrum Disorders (ASD), pervasive developmental disorders not otherwise specified (PDD-NOS), etc.

公开(公告)号：US20190201540A1

公开(公告)日：2019-07-04

申请号：US16304020

申请日：2017-05-24

Applicant: Bryce Chackerian ,  Alan Remaley ,  Ingrid Lindquist ,  Ingrid Lindquist ,  STC UNM

Inventor： Bryce Chackerian ,  Alan Ramaley ,  Ingrid Lindquist

IPC: A61K47/64 ,  A61K39/00 ,  A61K39/12 ,  A61K47/69 ,  C07K14/775 ,  A61P3/06 ,  C12N15/85

CPC classification number: A61K47/646 ,  A61K39/0005 ,  A61K39/12 ,  A61K45/06 ,  A61K47/6901 ,  A61K2039/62 ,  A61P3/06 ,  C07K14/775 ,  C12N15/85 ,  C12N2795/18123

Abstract: This disclosure describes immunogens, compositions, and methods for treating dyslipidemia. The immunogen included an ApoC3-derived peptide linked to a bacteriophage virus like particle (VLP) immunogenic carrier. The ApoC3 immunogen can be administered to a subject having, or at risk of having, dyslipidemia. The ApoC3 immunogen may be administered alone or co-administered with an additional dyslipidemia therapeutic agent.